%0 Journal Article %1 Wittmann.2007 %A Wittmann, S. %A Zirn, B. %A Alkassar, M. %A Ambros, P. %A Graf, N. %A Gessler, M. %D 2007 %J Genes Chromosomes Cancer %K *Chromosome *Chromosomes;Human;Pair *Chromosomes;Pair 11 16 Anaplasia/*genetics Deletion Humans Neoplasm Prognosis Recurrence;Local/*genetics Tumor/diagnosis/*genetics/pathology/prevention Wilms control {\&} %N 2 %P 163--170 %T Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis %V 46 %X Allele loss of chromosome arms 11q and 16q in Wilms tumors has been associated with different clinical parameters in prior studies. To substantiate these findings in a large collection of tumors treated according to the GPOH/SIOP protocol and to narrow down critical regions, we performed loss of heterozygosity (LOH) analyses of chromosome arms 11q and 16q on 225 Wilms tumors. On chromosome arm 11q an overall rate of allele loss of 19.6\% (44 of 225 tumors) was found using eleven markers that were almost evenly distributed along the long arm. Chromosome arm 16q was analyzed with six markers selected from gene-rich regions that identified an LOH rate of 18.4\% (41/223). Evaluation of LOH with respect to clinical data revealed significant associations of LOH 11q with histology: LOH 11q was 3-4 times more frequent in mixed type and diffuse anaplastic tumors. In contrast, epithelial as well as stromal type tumors never exhibited allele loss on 11q. Furthermore, a significant correlation with tumor recurrence and death was detected, but only for tumors that lost the entire long arm of chromosome 11. Similarly, LOH 16q was correlated with higher risks of later relapse, especially in tumors with complete loss of the long arm. Hence, analyses of LOH on 11q and 16q appear to be helpful to identify tumors with a higher risk of relapse and adverse outcome, which need adjusted therapeutic approaches.

@article{Wittmann.2007, abstract = {Allele loss of chromosome arms 11q and 16q in Wilms tumors has been associated with different clinical parameters in prior studies. To substantiate these findings in a large collection of tumors treated according to the GPOH/SIOP protocol and to narrow down critical regions, we performed loss of heterozygosity (LOH) analyses of chromosome arms 11q and 16q on 225 Wilms tumors. On chromosome arm 11q an overall rate of allele loss of 19.6{\%} (44 of 225 tumors) was found using eleven markers that were almost evenly distributed along the long arm. Chromosome arm 16q was analyzed with six markers selected from gene-rich regions that identified an LOH rate of 18.4{\%} (41/223). Evaluation of LOH with respect to clinical data revealed significant associations of LOH 11q with histology: LOH 11q was 3-4 times more frequent in mixed type and diffuse anaplastic tumors. In contrast, epithelial as well as stromal type tumors never exhibited allele loss on 11q. Furthermore, a significant correlation with tumor recurrence and death was detected, but only for tumors that lost the entire long arm of chromosome 11. Similarly, LOH 16q was correlated with higher risks of later relapse, especially in tumors with complete loss of the long arm. Hence, analyses of LOH on 11q and 16q appear to be helpful to identify tumors with a higher risk of relapse and adverse outcome, which need adjusted therapeutic approaches.}, added-at = {2013-01-29T13:47:26.000+0100}, author = {Wittmann, S. and Zirn, B. and Alkassar, M. and Ambros, P. and Graf, N. and Gessler, M.}, biburl = {https://www.bibsonomy.org/bibtex/275de03335109a8d660d0b23737d73423/ebch}, interhash = {e2b432faabbec5323b2d7560650b233a}, intrahash = {75de03335109a8d660d0b23737d73423}, journal = {Genes Chromosomes Cancer}, keywords = {*Chromosome *Chromosomes;Human;Pair *Chromosomes;Pair 11 16 Anaplasia/*genetics Deletion Humans Neoplasm Prognosis Recurrence;Local/*genetics Tumor/diagnosis/*genetics/pathology/prevention Wilms control {\&}}, number = 2, pages = {163--170}, timestamp = {2013-01-29T13:47:31.000+0100}, title = {Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis}, volume = 46, year = 2007 }